Our 70,000 square-foot radioligand therapy (RLT) manufacturing site in Indianapolis, Indiana, opened in 2024. RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue. The site is being expanded to enable in-house production of isotopes, a critical radioactive component of these therapies.
Key Facts About the Site
2024
70K
1 of 5
See Photos from Our Indianapolis Site
Learn more about how we’re expanding our site in Indianapolis to include isotope production and see our Wall of Hope, where we place a ribbon to honor each patient who receives a dose of RLT.
-
View
1/4 -
View
2/4 -
View
3/4 -
View
4/4
Featured Stories
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future
As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
Novartis in San Diego: A Quarter Century of R&D Innovation
A look back at a legacy of biomedical research breakthroughs that trace their roots to our San Diego site.
How This Former Army Officer Helps Deliver Cancer Treatments to Patients
Radioligand therapies harness the power of radioisotopes to target cancer with precision. For Matt Baca, delivering a dose in a three-to-five-day window is all in a day’s work.
